Blog

Vincent Rajkumar: The 4 big myeloma randomized trials to watch out for ASCO24

Photo from Vincent Rajkumar/X

Jun 2, 2024, 23:06

Vincent Rajkumar: The 4 big myeloma randomized trials to watch out for ASCO24

Vincent Rajkumar shared a post on X:

“The 4 big myeloma randomized trials to watch out for ASCO24

1. Isa-VRd vs Isa-Rd newly diagnosed
2.Isa-VRd vs VRd (IMROZ)
3.DREAMM8 Bela-Pd vs Pd
4.Ven Dex vs Pom Dex (Canova).

1) The Triplet vs Quad trials with will define role of quads in elderly patients with newly diagnosed myeloma. They also provide frontline phase III data with Isatuximab— and a choice between Dara and Isa. For some patients Isa will be more cost effective.

2) Belantamab will make a comeback. Corneal toxicity is low with reduced frequency dosing. The drug works very well. And in many patients with refractory myeloma belantamab may be safer and easier to do than bispecifics. We need options.

3) Venetoclax trial result interpretation needs to be careful. I do not want to disregard an effective drug. In t11:14, Venetoclax has a role. Venetoclax does not need to be better than Pom for clinical benefit. This trial is important.”

Source: Vincent Rajkumar/X

Vincent Rajkumar is a Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, and Chair for the Mayo Clinic Myeloma, Amyloidosis, and Dysproteinemia Group. He also chairs the Board of directors of The International Myeloma Foundation and the Eastern Cooperative Oncology Group (ECOG) Myeloma Committee. His extensive contributions include over 230 peer-reviewed publications, predominantly focusing on multiple myeloma and related plasma cell disorders. Furthermore, Dr. Rajkumar is a Section Editor for multiple myeloma and related disorders for Leukemia and an Associate Editor for the Mayo Clinic Proceedings.